Deferasirox

ANDA 211852, held by Cipla. Deferasirox.

As of Nov 15, 2026, ANDA 211852 (Deferasirox), held by Cipla, was first approved by FDA on Jun 15, 2020, with 0 approved supplements and 0 published complete response letters.

First approved: Jun 15, 2020
Review: Standard
Supplements approved: 0
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first


Jun 15, 2020	Original application	Approved	None posted
Feb 11, 2020	Original application	Approved	None posted

Products

3 strengths and forms


Deferasirox90MG · tablet;oral	Deferasirox	Discontinued
Deferasirox360MG · tablet;oral	Deferasirox	Discontinued
Deferasirox180MG · tablet;oral	Deferasirox	Discontinued

Identifiers

Application: ANDA 211852
Drugs@FDA: Overview at FDA
Company: Cipla

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters